Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche span> par promoteur : Amgen, Inc
Femme et Homme Max 99 ans
Amgen, Inc
MAJ Il y a 5 ans
GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas
To determine if the treatment of AMG 479 at 12 mg/kg and/or 20 mg/kg in combination with gemcitabine improves overall survival (OS) as compared with placebo in combination with gemcitabine in subjects...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Amgen, Inc
MAJ Il y a 5 ans
A study to find out more about the effect of AMG 181 in people with moderate to severe ulcerative colitis Μια Μελέτη για την εύρεση περισσοτέρων δεδομένων σχετικά με την επίδραση του AMG181 σε ασθενείς με Μέτρια έως Σοβαρή Ελκώδη Κολίτιδα
To evaluate the effect of AMG 181 on induction of remission in subjects with moderate to severe UC at week 8 as assessed by a total Mayo Score ≤ 2 points, with no individual subscore > 1 point
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Amgen, Inc
MAJ Il y a 5 ans
Study to assess the long term safety and efficacy of AMG 145 in patients with high concentrations of lipids in the blood
To characterize the safety and tolerability of long-term administration of AMG 145
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Amgen, Inc
MAJ Il y a 5 ans
A study to find out more about the effect of AMG 181 in people with moderate to severe Crohn's Disease
To evaluate the efficacy of AMG 181 as measured by the proportion of subjects achieving Crohn’s Disease Activity Index (CDAI) remission (CDAI < 150) at week 8
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Amgen, Inc
MAJ Il y a 5 ans
Study to determine the adequate dose of a new medicine omecantiv mecarbil compared to placebo in patients with a heart condition whereby the ability of the heart to pump enough blood to meet the body’s need at all times is reduced
(i) to select an oral modified release (MR) formulation and dose of omecamtiv mecarbil for chronic twice daily (BID) dosing in subjects with HF and left ventricular systolic dysfunction and (ii) to c...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Amgen, Inc
MAJ Il y a 5 ans
A study investigating the use of Omecamtiv Mecarbil on subjects with heart failure
To evaluate the effect of treatment with omecamtiv mecarbil compared with placebo on the time to cardiovascular (CV) death or first HF event, whichever occurs first, in subjects with chronic HF with r...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Amgen, Inc
MAJ Il y a 5 ans
A Randomized, Double-Blind, Placebo Controlled, Multiple Dose Phase 2 Study to Determine the Safety and Efficacy of AMG 853 in Subjects with Inadequately Controlled Asthma
The primary objective is to determine if AMG 853 is effective compared with placebo as measured by change in Asthma Control Questionnaire (ACQ) symptom scores from baseline to week 12.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Amgen, Inc
MAJ Il y a 5 ans
A Global, Multicenter, Open-label, Single Agent, Two-stage Phase 2 Study to Evaluate the Efficacy and Safety of AMG 102 in Subjects With Advanced Renal Cell Carcinoma
To assess objective response rate in subjects with advanced renal cell carcinoma receiving AMG 102 treatment.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Amgen, Inc
MAJ Il y a 5 ans
Study designed to evaluate the safety and efficacy of Evolocumab compared with placebo, in people with diabetes who have high cholesterol and who are already taking statin treatment
To evaluate the effect of 12 weeks of subcutaneous (SC) evolocumab every 2 weeks (Q2W) and monthly (QM), in combination with oral (PO) atorvastatin daily (QD), compared with placebo Q2W and QM, in com...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Amgen, Inc
MAJ Il y a 5 ans
Efficacy and Safety Study of Romiplostim in Paediatrics with Immune Thrombocytopenia
The primary objective is to evaluate the efficacy of romiplostim in the treatment of thrombocytopenia in pediatric subjects with immune thrombocytopenia (ITP) as measured by durable platelet response.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Plus d'informations
Précédent
6
7
8
9
10
11
12
13
14
15
Suivant